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ABSTRACT
Proliferation of thyroid follicular cells is controlled by three intra-
cellular cascades [cAMP, inositol 1,4,5-triphosphate (IP3)/Ca
21/diac-
ylglycerol (DAG), and tyrosine kinases] that are activated by distinct
extracellular signals and receptors. We had previously generated a
transgenicmousemodel inwhich the cAMP cascadewas permanently
stimulated in thyroid cells by an adenosine A2a receptor (Tg-A2aR
model). In the present work, we have generated a transgenic model
characterized by the chronic stimulation of both adenylyl cyclase and
phospholipase C in thyroid follicular cells. The bovine thyroglobulin
gene promoter was used to direct the expression of a constitutively
activemutant of thea1B adrenergic receptor, which is known to couple
to both cascades in transfected cell lines. The expression of the trans-
gene resulted, as expected, in the activation of phospholipase C and
adenylyl cyclase, as demonstrated by the direct measurement of IP3
and cAMP in thyroid tissue. The phenotype resulting from this dual
stimulation included growth stimulation, hyperfunction, cell degen-
eracy attributed to the overproduction of free radicals, and the de-
velopment of malignant nodules invading the capsule, muscles, and
blood vessels. Differentiated metastases were found occasionally in
old animals. The development ofmalignant lesionswasmore frequent
and of earlier onset than in our previous Tg-A2aRmodel, in which only
the cAMP cascade was stimulated. These observations demonstrate
that the cAMP and IP3/Ca
21/DAG cascades can cooperate in vivo
toward the development of thyroid follicular cell malignancies. (En-
docrinology 138: 369–378, 1997)
THYROIDCELL function and proliferation are controlledby factors acting on different intracellular cascades
through the interaction with their specific membrane recep-
tors (1). The main regulator of thyroid function and growth
is TSH, a heterodimeric glycoprotein synthesized by pitu-
itary thyrotrophs, and acting on a thyroid specific G protein-
coupled receptor. TSH receptor activation leads to the stim-
ulation of the cAMP cascade in all investigated mammalian
species. It is well established that activation of the cAMP
cascade maintains differentiation of thyrocytes and leads to
the activation of both their function and proliferation (2–4).
A second cascade that has been shown to promote prolifer-
ation while inducing dedifferentiation in thyroid cells in
culture is the diacylglycerol (DAG)/protein kinase C branch
of the phospholipase C pathway (5, 6). Phospholipase C can
be stimulated in dog thyroid cells by acetylcholine (7); in
human thyroid cells by ATP, bradykinin, and TRH (8, 9); and
in rodent cells by a1-adrenergic agonists (10–12). Stimulation
of this cascade by the TSH receptor at high TSH concentra-
tions has also been demonstrated in the human thyrocyte
(13), but not in the dog thyrocyte (7). Stimulation of the
inositol 1,4,5-triphosphate (IP3)/Ca
21/DAG cascade has
been reported to promote H2O2 production (through the
stimulation of the ill defined H2O2-generating system), io-
dide organification, and thyroid hormone synthesis (9, 14,
15). The third cascade stimulating proliferation is the ty-
rosine kinase/ras/mitogen-activated protein kinase path-
way. Factors known to regulate this pathway in thyroid cells
include insulin-like growth factor I, epidermal growth factor
(EGF), and hepatocyte growth factor (3, 16, 17). Although
EGF and hepatocyte growth factor promote proliferation and
induce dedifferentiation of the thyroid cell, insulin-like
growth factor I and insulin have a permissive effect on the
mitogenic actions of TSH, EGF, and phorbol esters (6).
We have previously generated transgenic mouse lines ex-
pressing the adenosine A2a receptor under the control of the
thyroid cell-specific thyroglobulin promoter (18). Presum-
ably through the continuous release of adenosine by thyroid
tissue, the adenosine receptor expressed in thyroid cells acts
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as a constitutive activator of the cAMP cascade, leading to the
development of a toxic hyperfunctioning goiter. This trans-
genic model reproduces the pathogenesis and phenotype of
autonomous hyperfunctional adenomas and nonautoim-
mune familial hyperthyroidism secondary to the permanent
activation of adenylyl cyclase by constitutively active TSH
receptor mutants (19, 20). A similar, although milder, phe-
notype was obtained in mice expressing in their thyroid a
constitutively activated Gas, the G protein that activates ad-
enylyl cyclase (21).
With the aim of investigating the effect of the concomitant
stimulation of both the cAMP and IP3/Ca
21/DAGpathways
on thyroid function and proliferation in vivo, we generated
transgenic mouse lines expressing a mutant of the a1B-ad-
renergic receptor that activates both cascades (22). This mu-
tant was previously reported to be constitutively active in
transfected cell lines (23) and in heart muscle cells of trans-
genic mice (24). As expected from the stimulation of the
cAMP pathway, transgenics expressing the mutant a1B-re-
ceptor partially reproduced the phenotype of the mice ex-
pressing the A2a-adenosine receptor. Nevertheless, marked
differences were found in the function of the gland, the
evolution of the phenotype, and the frequency and timing of
malignant tumor development, all changes attributed to the
stimulation of phospholipase C.
Materials and Methods
Generation of transgenic mice for the bovine thyroglobulin-
a1B-adrenergic mutant receptor hybrid gene (Tg-a1BAR)
The coding region of the mutant (Arg288Lys, Lys290His, Ala293Leu)
(23) hamster a1B-adrenergic receptor complementary DNA (cDNA;214
to 11745 relative to the start codon) was cloned into the polylinker of
pSG5 (Stratagene, La Jolla, CA). A StuI-SalI restriction fragment of pSG5-
a1B comprising the second intron of the rabbit b-globin gene, the a1B
cDNA, and the polyadenylation signal was further cloned in pBluescript
SK1, downstream of a bovine thyroglobulin gene promoter fragment
(22036 to 19 bp relative to the CAP site).
Transgenic mice were generated as previously described (25). All
animals were anesthetized with either avertin or ether before surgical
procedures. Animals were kept at the central housing facility of the Free
University of Brussels Medical School, and all procedures involving
them were made in accordance with the regulations and guidelines of
the Belgian State and European Union after approval by the local ethical
committee. The linearized construct (1–2 pl of a 2.5 mg/ml solution) was
microinjected into the pronuclei of fertilized eggs from a C57BL/6J 3
DBA/2J F2 cross. Screening of transgenic animals was performed by
Southern blotting of DNA extracted from tail biopsies and hybridization
with a bovine thyroglobulin gene promoter probe.
Hormonal, functional, and second messenger assays
Blood samples were obtained by cardiac or orbital puncture under
anesthesia. Total T4 levels were assayed on sera by standard RIA (T4
Coat-a-Count, Clinical Assays, Cambridge, MA).
Iodide uptake was measured by counting whole thyroid glands 4 h
after an ip injection of [125I]NaI (15 mCi). Organification was assayed by
trichloroacetic acid (5%, wt/vol) precipitation of thyroid homogenates
as previously described (26). Protein-bound radioiodine was expressed
as a percentage of the total iodide uptake.
For cAMP measurements, thyroid glands were collected under an-
esthesia and immediately immersed in boilingwater. After 5min, tissues
were homogenized in a glass homogenizer, and insoluble material was
removed by centrifugation. The soluble fraction was lyophilized and
redissolved in water. cAMP was assayed by RIA following the kit
manufacturer’s instructions (cAMP125 assay system, RPA 509, Amer-
sham, Aylesbury, UK).
For inositol phosphate determinations, thyroid glands were collected
under anesthesia and flash-frozen in liquid nitrogen. They were thawed
in 1 ml ice-cold 5% perchloric acid and homogenized. After centrifu-
gation, supernatants were titrated to pH 7.5 with a solution containing
60 mmHEPES, 1.5m KOH, and Universal Indicator. Precipitated KClO4
was removed by centrifugation. Samples were purified using Amprep
SAX minicolumns (RPN 1908, Amersham), and IP3 was measured fol-
lowing the kit manufacturer’s instructions (d-myo-inositol 1,4,5-triphos-
phate 3H assay system, TRK 1000, Amersham).
Binding assays
Crude 40,000 3 g membrane fractions were prepared from thyroid
glands as previously described (27) and resuspended in binding buffer
[50 mm Tris-HCl (pH 7.4), 5 mm EDTA, and 150 mm NaCl]. Protein
content estimation was carried out using the Lowry assay, as modified
by Peterson (28). Binding assays were performed on 10–100 mg mem-
brane proteins, using the a1-specific antagonist 2-{b-(hydroxy-3-[
125I]io-
dophenyl)ethylaminomethyl}-tetralone (2200 Ci/mmol; New England
Nuclear, Hertfordshire, UK) as tracer at a saturating concentration (250
pm; reported Kd, 30–50 pm) (29). Nonspecific binding was determined
in the presence of a large excess (50 mm) of prazosin (Sigma Chemical
Co., St. Louis, MO). Incubations were performed for 1 h at 25 C in 250
ml binding buffer. Bound ligand was separated by filtration on GF-C
membranes (Whatman, Maidstone, UK) and counted.
Northern blotting procedure
Polyadenylated RNA was isolated using the FastTrack kit (Invitro-
gen, San Diego, CA). After glyoxal denaturation, RNA samples (15
mg/lane) were fractionated on a 1% agarose gel in 10 mm phosphate
buffer (pH 7.0) and transferred to nylon membranes (Pall Biodyne A,
Glen Cove, NY) as previously described (30). DNA probes were a-32P
labeled by random priming (31). After hybridization and washing, the
filters were autoradiographed using Amersham b-max films.
Histological and immunohistological procedures
For light microscopy, tissues were fixed by immersion for 24 h in
Bouin’s solution and embedded in paraffin by standard procedures.
Six-micron sections were stained with hematoxylin and eosin.
For determination of the proliferation index, bromodeoxyuridine
(BrdU) was injected ip (0.05 mg/g BW) 1 h before death. Thyroids were
fixed in 70% ethanol-30% acetic acid, embedded in paraffin, and cut at
6-mm intervals. BrdU was detected by immunochemistry (32), using a
mouse monoclonal anti-BrdU antibody (Becton Dickinson, Rutherford,
NJ), a sheep biotinylated antimouse Ig serum (Amersham), and a
streptavidin-biotinylated horseradish peroxidase complex (Amersham).
For semithin sections and electron microscopy, thyroids were fixed
by immersion for 2 h in 2.5% glutaraldehyde (Taab, Reading, UK) in 0.1
m cacodylate buffer, dehydrated in an ethanol series of increasing
strength, and embedded in LX112 (Ladd Research Industries, Burling-
ton, VT). Sections (0.5 mm thick) were cut and stained with 1% toluidine
blue for light microscopy. Ultrathin sections (30–40 nm) were cut and
mounted on copper grids, stained with uranyl acetate and lead citrate,
and examined on a Philips EM 301 electron microscope.
Statistical analysis
All presented data represent themean and sd. Statistical analysis was
performed by using the Graphpad Instat software. Student’s t test was
used to determine the statistical significance of the differences observed
among groups for the various parameters. When sds were significantly
different between groups (as determined by the F test), therefore pre-
venting the use of Student’s t test, logarithmic transformation of the data
was made before statistical analysis, or Welch’s alternate t test (33) was
applied instead.
Results
Generation of the mouse transgenic lines expressing the
mutant a1B-receptor
Six founder transgenic animals were generated, using a
hybrid gene that placed the constitutively active a1B-adren-
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ergic receptor cDNA under control of the bovine thyroglob-
ulin gene promoter (Fig. 1). Stable transgenic lines were
established by backcrossing the founder animals (DBA/2J 3
C57BL/6J F2 cross) with the C57BL/6J parental line. The
bovine thyroglobulin gene promoter was shown previously
in a number of transgenicmodels to be strictly specific for the
thyroid follicular cell (18, 26, 34–36). Expression of the trans-
gene was verified by Northern blotting, using an a1B-adren-
ergic receptor probe. a1B transcripts could not be detected in
the thyroid of control animals (not shown) or in that of other
transgenic lines displaying undifferentiated (Tg-AgT) (26) or
highly differentiated hyperfunctioning goiters (Tg-A2aR; Fig.
2 (18). Abundant transcripts were found in the thyroid of
transgenic animals (Fig. 2). Binding assays were also per-
formed to detect the presence of a1B-binding sites in thyroid
membranes of the transgenic mice. Using the specific a1-
adrenergic receptor antagonist 2-{b-(hydroxy-3-[125I]iodo-
phenyl)ethylaminomethyl}-tetralone as ligand, a small num-
ber of binding sites was found on wild-type mouse thyroid
membranes (mean6 sd, 96 2 fmol/mgmembrane proteins).
On membranes prepared from the thyroid of transgenic an-
imals (5 months old, line 51), a1-binding sites were increased
about 10-fold (mean 6 sd, 115 6 9 fmol/mg membrane
proteins), demonstrating the functional expression of the
transgene (not shown). In these conditions, the nonspecific
bindingwas 86 1 (mean6 sd) fmol/mgmembrane proteins.
The direct measurement of IP3 and cAMP in thyroid tissue
obtained from mice belonging to line 51 confirmed the ex-
pected dual stimulation of the IP3/Ca
21/DAG and cAMP
cascades (Fig. 3).
Phenotype of transgenic mice
In all six transgenic lines, animals appeared normal up to
the age of 6 months in terms of behavior and external ap-
pearance. In three lines (no. 51, 57, and 66), some of the mice
developed a goiter clearly visible from external inspection at
ages ranging from 6–24 months. A number of transgenics
aged 1 yr or more also died prematurely. Measurements of
circulating thyroid hormones demonstrated moderate to se-
vere hyperthyroidism in most animals of lines 51 and 57 and
in old animals of line 66 (see below). In the three other lines,
T4 levels were in the normal range.
Morphological analysis of the transgenic model
Animals of the six transgenic lines were killed at ages
ranging from birth to 24 months, and macroscopic or mi-
croscopic abnormalities were searched for in the thyroid and
other organs. Primary lesions were restricted to the thyroid,
as expected from the properties of the thyroglobulin gene
promoter directing the expression of the transgene. Themor-
phological changes, when present, were grossly similar in all
transgenic lines, but the timing of their appearance, and the
extent and frequency of alterations were variable from one
line to another. Structural abnormalities occurred earliest in
line 51; the evolution was somewhat slower in line 57 and
FIG. 1. Structure of the thyroglobulin-
a1B-adrenergic receptor transgene (Tg-
a1BAR) comprising the bovine thyroglob-
ulin (bTg) promoter, the rabbit b-globin
(rb-globin) second intron, and the cDNA
sequence encoding a constitutively active
mutant form of the hamster a1B-adren-
ergic receptor (ht a1BAR). The scale is
expressed as kilobases.
FIG. 2. Expression of the a1B-adrenergic receptor and differentiation
markers in transgenic animals expressing themutant a1B-adrenergic
receptor (Tg-a1BAR). Transcripts derived from the a1B transgene and
from the thyroid-specific genes thyroglobulin (Tg), thyroperoxidase
(TPO), and TSH receptor (TSHr) were detected by Northern blotting.
The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messen-
ger was detected as a control. Transgenic animals expressing the
large T viral oncogene (Tg-TAg) (25) and the A2a-adenosine receptor
(Tg-A2aR) (18) were assayed simultaneously as controls for undiffer-
entiated and hyperfunctional thyroid tissues, respectively. Each lane
contains 15 mg polyadenylated RNA prepared from 4-month-old an-
imals (line 51 for Tg-a1BAR mice). Note the lack of detectable a1B
transcripts in Tg-TAg and Tg-A2aR transgenic mice.
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was much delayed in line 66. In the other three lines (no. 23,
36, and 40), themorphological alterationsweremoderate and
of late appearance. This evolution was correlated with the
serum thyroid hormone levels; lines 51 and 57 were the two
lines that exhibited severe hyperthyroidism from birth,
whereas animals from line 66 became hyperthyroid at later
stages (Fig. 3). The evolution was also correlated with the
abundance of transgene-derived transcripts in the thyroid as
determined by Northern blotting; transcripts were more
abundant in line 51 than in line 57 or 66 (data not shown).We
focused most of the analysis on the transgenic lines display-
ing the strongest phenotype. Functional assays were per-
formed essentially on animals from line 51, histological data
were collected mostly from animals from lines 51, 57, and 66.
Wewill first describe themorphological changes observed in
line 51. The variation in phenotypic development in the other
lines will be described later.
The thyroids from mice of line 51 were increased in size
from the first weeks of life, and some reached a weight of 130
mg by 12 months (control, 2 mg). The enlargement was
regular and symmetrical (Fig. 4, A and B), and the general
organization into follicleswas preserved. The structure of the
gland and the cell morphology were, nevertheless, altered.
Normal thyroid tissue consists of round or ovoid follicles of
FIG. 3. Characterization of the func-
tional and proliferative status of the
thyroid gland in Tg-a1BAR transgenic
mice. 125I uptake, 125I organification,
and protein-bound iodine were mea-
sured, as described in Materials and
Methods, in 1-, 2-, 6-, and 13-month-old
animals of line 51 and 1-, 3-, and 13-
month-old controls. At least three ani-
mals per group were tested. The values
were not significantly different between
the control age groups, and the values
were pooled (C; n 5 9). For transgenics,
the values were pooled for 1- and
2-month-old animals (,2 m; n 5 6) and
for 6- and 13-month-old animals (.6 m;
n5 9). IP3 levels were measured in thy-
roid tissue from 3.5-month-old control
(C) and transgenic (T) mice from line 51
and expressed as picomoles per mg wet
weight (n 5 4). cAMP levels were mea-
sured by RIA on thyroids from 2.5-
month-old control (C) and transgenic
(T) mice from line 51 and expressed as
picomoles per mg wet weight (n 5 3).
The BrdU index was estimated by
counting the percentage of labeled nu-
clei in 2-week-old (2w), 2-month-old (2
m), 6-month-old (6 m), and 13-month-
old (13m) control (C) and transgenic (T)
mice from line 51 (n5 4 for controls; n5
5 for transgenics). T4 was measured in
control mice (C) and transgenics (T)
from the various lines (lines 51, 57, and
66 and the three other lines). Pooled
values for animals less than 5 months
(,5 m) and more than 12 months (.12
m) of age are given. P values are given
for transgenic groups compared to con-
trols (n 5 6 for control groups, n 5 32
and 35 for line 51, n5 13 and 13 for line
57, n 5 4 and 25 for line 66, n 5 12 and
15 for other lines). In all cases, the error
bar represents the SE. Statistical anal-
ysis was made using Student’s t test
whenever SDs were not significantly dif-
ferent between groups. Logarithmic
transformation of the data was made
before statistical analysis for iodine up-
take and organification. Welch’s alter-
nate t test (33) was used for T4 data for
lines 51, 57, and 66 and for BrdU data
for 6-month-old animals.
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relatively regular size and shape, lined with a cuboidal ep-
ithelium. In transgenic animals expressing the mutated a1B-
adrenergic receptor, clusters of densely packed cells forming
narrow or branched follicular-like structures (Fig. 4C) and
irregularly shaped follicles with numerous papillary infold-
ings (Fig. 4D) were frequent. Large follicles with weakly
eosin- or periodic acid-Schiff-stained colloid were also
found. Abundant cell debris, macrophages, monocytes, and
neutrophils were present in the colloid. Follicles were lined
by flattened epithelial cells (Fig. 4F) or by cylindrical or
cuboidal cells (Fig. 4D). The cells sometimes displayed a
pseudostratified organization, with nuclei found at all levels
of the epithelium (Fig. 4E). Nuclei were round and regularly
shaped, with a normal chromatin organization (Fig. 4E). Ne-
crotic cells with condensed nuclei were frequently found in
the epithelium or lumen (Fig. 4F). The apical region of the
cells was often protruding into the lumen and was vacuolar,
presenting an “empty” aspect (Fig. 4E). Ultrastructural anal-
ysis attributed this clear aspect to the presence of large cy-
toplasmic vesicles containing electron-lucent material (Fig.
5A) or markedly dilated cisternae of the rough endoplasmic
reticulum (Fig. 5B) that sometimes occupied most of the cell
volume. Electron-dense inclusions with homogeneous or
heterogeneous contents were frequent (Fig. 5, A and B). Mi-
toses (Fig. 5H) were found with a relatively high frequency
(they are extremely rare in the thyroid of adult controls).
Bromodeoxyuridine incorporation confirmed the higher pro-
liferation rate of thyroid cells in transgenic animals com-
pared to controls (Fig. 3). Vascularization of the thyroid was
normal or moderately increased compared to that in control
animals.
The organization of the gland became increasingly heter-
ogeneous with age, with the appearance and growth of ac-
tively proliferating nodules (Figs. 4, C and B, and 6A). The
mean size and number of the nodules increased with the age
of the animals, and their higher proliferation rate was con-
firmed by BrdU incorporation (not shown). The nodules
were usually homogeneous and displayed various architec-
tural and differentiation patterns. They were generally more
indicate the limits of the thyroid lobes. The nodular structure of the
transgenic mouse thyroid is obvious, with the presence of areas of
dense tissue and otherswhere the follicular lumina are clearly visible.
Scale bars 5 750 mm. C, Low magnification view of the thyroid from
a 1.5-month-old transgenic mouse from line 51 (fixed in Bouin’s fluid
and embedded in paraffin). The gland consists of follicles as well as
clusters of densely packed cells forming narrow strands of branched
follicular-like structures. Scale bar 5 125 mm. D–F, Low magnifica-
tion view of the thyroid from a 2.5-month-old transgenic mouse
(glutaraldehyde-osmium fixed and embedded in plastic). D, The fol-
licular lumina are unevenly divided by papillae containing a conjonc-
tivo-vascular septum. Note the presence of pyknotic nuclei in the
lumen. Scale bar 5 50 mm. E, In some areas, the epithelium displays
a pseudostratified appearance, with staggered nuclei; some of them
are pyknotic, and many epithelial cells have a vacuolar appearance.
Scale bar5 20mm.F, At the periphery of the gland, large follicleswith
flattened epithelium are seen. Note the presence of cell debris inside
the lumen. Scale bar5 40 mm. G, Partial view of a large nodule in the
thyroid from a 16-month-old transgenic mouse from line 66 (fixed in
Bouin’s fluid and embedded in paraffin). Large follicular spaces are
lined by regularly organized papillae. Scale bar 5 50 mm. H, High
magnification view of two mitoses (metaphase and anaphase) in the
thyroid of a 12-month-old transgenic mouse from line 66. Scale bar 5
10 mm.
FIG. 4. Morphological pattern of the thyroid from transgenic mice
expressing the mutant a1B-adrenergic receptor. A and B, Gross ap-
pearance of the thyroid from a 4-month-old transgenic animal
from line 51 (B) and a nontransgenic littermate (A). The arrows in A
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dense than the surrounding tissue, and the structural orga-
nization included follicular, microfollicular, papillary, tra-
becular, and solid masses, with a higher frequency of pap-
illary structures. The cell morphologywas sometimes similar
to that of the surrounding thyroid gland, but most of the
nodules completely lost their clear cell aspect. In large nod-
ules, foci of cells were found, with large nuclei adopting
morphological criteria that characterize humanpapillary car-
cinomas (ground glass aspect, pseudoinclusions; Fig. 6B). In
a few cases, allmorphological criteria of thyroid follicular cell
differentiation were lost; spindle cell foci were found, with-
out formation of identifiable follicles (Fig. 6C). The nodules
were never encapsulated. They frequently acquired struc-
tural characteristics that are consideredmalignant criteria for
human thyroid tumors. In these cases, the capsule surround-
ing the gland became markedly thickened, irregular, and
frequently invaded by the growing nodule (Fig. 6A); local
invasion also involved muscular tissue. Some of the nodules
appeared highly vascularized, to the point that areas of the
gland were transformed into vascular lakes filled with digi-
tations of thyroid tissue (Fig. 6D). When this feature was
encountered, invasion of blood vessels, vascular emboli in
large capsular or pericapsular veins (Fig. 6E), as well as
differentiated lung metastases (Fig. 6F) were frequently ob-
served. The overall frequency of lung metastases was esti-
mated to be 20% in animals over 12 months of age.
As stated above, the morphological phenotype of the an-
imals in line 57 was grossly similar to that in line 51, but
delayed. The clear cell aspect was present from the first
weeks of life, but was less obvious. Papillary proliferation
was found in early stages, and nodules with various archi-
tectures appeared with a high frequency in older animals. In
line 66, themorphology of the thyroidwas normal during the
first months, but nodules (often solitary) appeared in almost
all animals and became typically much larger than those in
lines 51 and 57 (the morphology of one of these nodules is
shown in Fig. 4G). In animals more than 15 months of age,
the largest goiters were found in mice derived from line 66,
and these goiters resulted generally from a single large nod-
ule per lobe. Some of the most malignant phenotypes were
also found in these mice (Fig. 6, C, D, and E), and the cir-
culating T4 levels generally correlated with the size of the
goiter. For the three other transgenic lines, mild alterations
were found in old animals, including a slight increase in
thyroid size and heterogeneity in follicle size and shape (not
shown). Small papillary nodules were occasionally found.
None of these animals was hyperthyroid.
Functional and proliferative status of the thyroid gland
Thyroid hormone levels reflected the functional activity of
the gland; they were elevated in most animals from lines 51
and 57 (Fig. 3). In line 51, youngmice were hyperthyroid, but
older mice with large nodules were characterized by a wider
range of T4 measurements, presumably resulting from the
functional properties of the individual nodules. As a result,
the mean T4 level in line 51 exhibited only a mild increase
with age (Fig. 3). In line 57, young animalswere hyperthyroid
as well, and mean T4 levels increased strongly with age and
the development of secondary nodules (Fig. 3). In line 66, T4
levels were normal during the first months of age and in-
creased significantly in older animals bearing large nodules
(Fig. 3), suggesting that in this line, most nodules were in-
deed functional.
Iodide uptake and organification were estimated after ip
injection of [125I]NaI in animals (1, 2, 6, and 13 months)
belonging to line 51. Uptake and organification were in-
creased compared to those in controls, in proportion to the
weight of the gland (Fig. 3). The efficiency of iodine incor-
poration into iodoproteins (protein-bound radioiodine) was
similar in transgenic and control animals at all ages (Fig. 3).
The proliferation rate was assayed by measuring the per-
centage of cells labeled after a single ip injection of BrdU. This
measurement was made on animals from line 51 at different
ages (Fig. 3). Compared with control animals, which show
very little thyroid cell turnover after the first few weeks of
life, the labeling index of transgenic thyroidswasmaintained
at a higher level throughout life, although it decreased
progressively.
The expression level of thyroid-specific genes was inves-
tigated by Northern blotting in the thyroids of mice trans-
genic for the mutant a1B-adrenergic receptor and was com-
pared to that in other transgenic lines characterized by
dedifferentiation (simian virus 40 large T antigen expression,
Tg-TAg) or hyperfunctioning (A2a-adenosine receptor ex-
pression, Tg-A2aR) of the thyroid cell (Fig. 2). Controls were
tested in parallel, but the amount of messenger RNA ob-
tained was much lower than that in the transgenic lines, and
the results are not shown in the figure. Thyroglobulin, thy-
roperoxidase, and TSH receptor transcripts were all present
in the thyroid of Tg-a1BAR mice, although they were less
abundant than in Tg-A2aR mice. Compared to controls, there
was an increase in thyroperoxidase and TSH receptor tran-
scripts and a decrease in thyroglobulin transcripts (not
shown). The three differentiationmarkers were undetectable
in Tg-TAg mice, as previously described (26).
Discussion
In our previous Tg-A2aR transgenic mouse model, the
expression of the wild-type A2a-adenosine receptor under
control of the bovine thyroglobulin gene promoter resulted
in a permanent activation of the cAMP cascade. This led to
a strong stimulation of thyroid cell function and the devel-
opment of a large goiter, confirming the main role of this
cascade in the in vivo control of thyroid cell function and
proliferation (18). In the long run, focal malignant lesions
were found, demonstrating that wild type Gs-coupled re-
ceptors can act as oncogenic proteins, when ectopically
and/or overexpressed (Ledent, C., unpublished observa-
tions). The A2a-adenosine receptor has not been reported to
be coupled to signaling pathways other than adenylyl cy-
clase, and we verified experimentally that this receptor did
not activate phospholipase C (Ledent, C., unpublished ob-
servations). In humans and rodents, some of the thyroid cell
functions (H2O2 generation and incorporation of iodine into
iodoproteins) are under the control of the IP3/Ca
21/DAG
cascade. The DAG/protein kinase C arm of this cascade also
promotes proliferation and dedifferentiation of the thyroid
cell in vitro (6), and the TSH receptor stimulates both adenylyl
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cyclase and phospholipase C in human thyrocytes. To verify
in vivo the roles attributed to phospholipase C activation in
thyroid follicular cells, we decided to generate a transgenic
model inwhich both the cAMPand IP3/Ca
21/DAGcascades
would be stimulated permanently.
Constitutive activity of G protein-coupled receptors was
first described (23) for an a1B-adrenergic receptor mutated in
the third cytoplasmic loop (Arg288Lys, Lys290His, and
Ala293Leu). This mutant receptor was characterized by a
marked increase in affinity for agonists (but not antagonists)
and by a basal coupling to Gq in the absence of agonists (23).
Expression in NIH-3T3 cells demonstrated the transforming
potential of the mutant (29). This mutant was recently used
to generate transgenicmice under the control of thea-myosin
heavy chain, leading to heart muscle-specific expression and
cardiac hypertrophy (24). TheAla293.Leumutation has been
shown to contribute to the constitutive properties of this
mutant receptor, as any amino acid substitution at position
293 led to increased basal activity (37). Although their main
signaling pathway is through phospholipase C, the a1B re-
ceptor, itsmutants, aswell as othera1 receptor subtypeswere
shown to also activate the cAMP pathway in tissues or trans-
fected cell lines (22, 38–40) (Cotecchia, S., unpublished ob-
servations) by direct (Gs activation) and indirect mech-
anisms.
a1B mutant receptors, therefore, appeared as an ideal
means of constitutively activating phospholipase C and ad-
enylyl cyclase in transgenic mice. A hybrid gene was engi-
neered by placing the mutant receptor (23, 41) under the
control of the bovine thyroglobulin gene promoter. This Tg-
a1BAR construct was used to generate six transgenic lines.
The expression of the transgene was confirmed by Northern
blotting, and the presence of functional a1-adrenergic recep-
tors in thyroid tissue was determined by ligand binding
assays. Direct measurements of cAMP and IP3 levels in the
thyroids of transgenic animals confirmed the dual stimula-
tion of adenylyl cyclase and phospholipase C by the mutant
receptor. The stimulation of the cAMP pathway, however,
was weaker than that in our previous Tg-A2aR model (18).
Thiswas not unexpected from amutant receptorwhosemain
coupling is through the phospholipase C pathway.
Mice belonging to the Tg-a1BAR lines developed a phe-
notype including hyperthyroidism and the development of
thyroid nodules, ultimately leading to malignant tumors.
This phenotype, however, was quite variable in its intensity
and in the timing of its appearance from one line to another.
This variability was correlated to the level of expression of
the transgene. We reported previously, using the bacterial
chloramphenicol acetyltransferase gene as reporter gene,
that the expression from the thyroglobulin gene promoter in
transgenic mice is highly variable from line to line (34).
Variability in the expression level and in the severity of the
phenotype was observed for other transgenes expressed un-
der the dependence of the same promoter (18, 26, 36). Such
variability is believed to be dependent on the site of inte-
gration of the transgene in the mouse genome.
Animals from lines 51 and 57weremarkedly hyperthyroid
from birth, whereas mice from line 66 developed hyperthy-
roidism only in association with the growth of large nodules
in their thyroid. The serum T4 values of young animals (,5
months old) did not reach the high levels that characterized
Tg-A2aR mice (18), in accordance with the lower stimulation
of the cAMP cascade in the Tg-a1BAR model. Nevertheless,
with the development of nodules in older animals (.5
months old) from lines 57 and 66, T4 values reached levels
similar to those in the Tg-A2aR model. The Tg-a1BAR mice
also exhibited a high capacity for taking up iodine and in-
corporating it into iodoproteins. As expected and similar to
the situation in our previous Tg-A2aRmodel, activation of the
cAMP cascade by the mutant a1B-adrenergic receptor re-
sulted in stimulation of thyroid function.
There were, however, marked differences between the
present Tg-a1BAR mice and our previous Tg-A2aR model.
The thyroids from lines 51 and 57were characterized by clear
follicular cells filled with large vacuoles resulting from or-
ganellar degeneration and by a high frequency of cell ne-
crosis. This was never encountered in the Tg-A2aR model, in
which the epithelium lining the follicles was normal, and
FIG. 5. Ultrastructure of the thyroid cells in a 5.5-month-old trans-
genic mouse from line 51 (glutaraldehyde-osmium fixed and embed-
ded in plastic). A, Large electron-lucent vesicles are found in the
cytoplasm in association with numerous dense bodies. Scale bar 5 2
mm. B, In cells budding into the lumen, cisternae of rough endoplas-
mic reticulum are highly dilated. Note the presence of heterogeneous
dense bodies. Scale bar 5 1.2 mm.
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necrosis was exceptional. Such degeneration of follicular
cells has been shown to occur in situations characterized
by an excessive production of free radicals (42). This aspect
of the phenotype can be attributed to the stimulation of the
IP3/Ca
21/DAG cascade, in agreement with the in vitro
demonstration that phospholipase C stimulates the H2O2
generation system and iodine organification in thyroid
cells (9, 43). Cell degeneracy was prominent in line 51,
where cell necrosis appeared to balance proliferation; de-
spite a high index of bromodeoxyuridine incorporation,
the goiters did not grow as large as in other lines (no. 57
and 66). In line 51, many nodules that ultimately grew to
a large size had often lost their clear cell morphology,
probably as a consequence of a selection process. In sup-
port of this view, the T4 level in animals from line 51 did
not correlate with the size of the gland, suggesting that
most of the large nodules were poorly active. In animals
from line 57, cell degeneracy was less pronounced, and the
selection against functional activity was reduced, as T4
levels increased readily with the development of nodules.
Clear cells were not observed in young animals from the
other lines in agreement with their overall milder
phenotype.
Another marked difference with the Tg-A2aR model was
the rapid development of nodules, and their frequent evo-
lution toward malignancy. Multiple nodules developed in
lines 51 and 57, whereas animals from line 66 developed late,
but very aggressive, functional nodules. Vascular invasion
and lung metastases were relatively frequent in old animals.
The higher malignancy of this model compared to that of the
Tg-A2aR mice is presumably due to concomitant stimulation
of phospholipase C and adenylyl cyclase. It has been shown
in vitro that the DAG/protein kinase C arm of the cascade,
if stimulated long enough, can promote the growth and
FIG. 6. Views of the thyroid from transgenic mice expressing the mutant a1B-adrenergic receptor (fixed in Bouin’s fluid and embedded in
paraffin). A, A nodule has penetrated the capsule in the gland of a 12-month-old animal from line 51. Note the thickening of the interrupted
original capsule and the formation of a new capsule around the invading tissue. Scale bar 5 150 mm. B, Foci of cells with large irregular nuclei
with pseudoinclusions and prominent nucleoli observed in a 3-month-old mouse from line 57. Scale bar 5 10 mm. C, In some areas, cells have
a spindle-like shape and do not form follicles (within a large nodule of a 17-month-old mouse from line 66). Scale bar 5 25 mm. D, In highly
vascularized nodules, blood vessels form vascular lakes containing digitations of thyroid tissue (17-month-old mouse from line 66). Scale bar 5
65 mm. E, In the capsule, vascular permeation of glandular tissue is observed (16-month-old mouse from line 66). Scale bar 5 30 mm. F, Partial
view of the lung of a 19-month-old mouse from line 66, showing one of the multiple differentiated metastases deriving from the thyroid tumor
that were found in this animal. Scale bar 5 200 mm.
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dedifferentiation of thyroid cells (6). We demonstrate here in
vivo that chronic phospholipase C stimulation can cooperate
with the cAMP pathway toward proliferation and transfor-
mation, without affecting the differentiation of thyroid cells.
In conclusion, this work demonstrates that the perma-
nent activation of both phospholipase C and adenylyl
cyclase in the thyroid follicular cell of transgenic mice
promotes as phenotypic characteristics stimulation of
function, induction of cell degeneration attributed to the
overproduction of free radicals, stimulation of prolifera-
tion, and tumor growth. Signs of malignancy, including
vascular invasion, appear more frequently and earlier than
in previous transgenic models. The present mouse lines
constitute the most aggressive transgenic model of differ-
entiated thyroid tumors to date, as the result of the ex-
pression of a single transgene. This model also demon-
strates that membrane receptors coupled to phospholipase
C may cooperate with the simultaneous stimulation of the
cAMP cascade and contribute to the development of thy-
roid follicular cell malignancies. The possible relevance of
our transgenic model for human cancer will require a
search for genetic events (such as mutations in receptor
genes) resulting in constitutive stimulation of the phos-
pholipase C pathway in thyroid tumors.
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